Riccur Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 3.50 Cr
- Revenue Growth -58.54%
- Profit Growth -17.98%
- Ebitda 11.02%
- Net Worth 5409.82%
- Total Assets -47.06%
About Riccur Pharma
Riccur Pharma Private Limited (RPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 08 November 2011 and has a history of 13 years and three months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹3.50 Cr.
Kishore Choudhary and Sundarpalsing Arneja serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH2011PTC223699
-
Company No.
223699
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Nov 2011
-
Date of AGM
30 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Riccur Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kishore Choudhary
|
Director | 17-Mar-2020 | Current |
|
Sundarpalsing Arneja
|
Director | 16-Jan-2019 | Current |
Financial Performance of Riccur Pharma.
Riccur Pharma Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 58.54% decrease. The company also saw a substantial fall in profitability, with a 17.98% decrease in profit. The company's net worth Soared by an impressive increase of 5409.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Riccur Pharma?
In 2019, Riccur Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Vivaan Prime Properties LlpKishore Choudhary is a mutual person
-
Vivaan Chemindia Private Limited
Kishore Choudhary is a mutual person
-
Vivaan Bhoomi Private Limited
Kishore Choudhary is a mutual person
-
Ringme Gadgets Private Limited
Sundarpalsing Arneja is a mutual person
Charges (Loans)
₹35.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 3.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jul 2019 | Others | ₹3.50 Cr | Open |
How Many Employees Work at Riccur Pharma?
Unlock and access historical data on people associated with Riccur Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Riccur Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Riccur Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
